Register Today!
Featuring…
Better Integrating Clinical and Preclinical Safety to Achieve Translational Safety
James Milligan, M.D., Safety Science Expert/Safety Physician, Clinical Safety, AstraZeneca
Idiosyncratic DILI: How Good are Currently Available Biomarkers and Which New Biomarkers Should We Look for?
Arie Regev M.D., Chair, Liver and GI Safety Committee, Global Patient Safety, Eli Lilly & Company
Bridging the Gap between Preclinical Data, Clinical Studies and Post-Approval Drug Safety
Phil Sager, M.D., Vice President, Clinical Research, Head, CV/Metabolic Clinical Development, Gilead
Achieving the Promise of Translational Research: Overcoming Scientific and Organization Challenges to Improve Early Risk Assessment
Stephen Furlong, Ph.D., Safety Science Lead, US Patient Safety, AstraZeneca
Idiosyncratic Liver Injury: Challenges and Approaches
Paul Watkins, M.D., Verne S. Caviness Distinguished Professor of Medicine, Professor of Pharmacotherapy, University of North Carolina Chapel Hill
Use of Informatics Approaches for Establishing a Threshold of Toxicological Concern
Sandeep Modi, Ph.D., Cheminformatician, Safety & Environmental Assurance Centre, Unilever; former Research Associate, GlaxoSmithKline
Special Panel hosted by DSEC: What Predictive Safety Technologies are Being Utilized Upstream and How They May Impact Clinical and Post-Approval Safety
Interactive Breakout Discussion Groups
.jpg?n=7969)
Complimentary Webinar
Keys to Gaining Widespread Adoption of Your Predictive Safety Platform
Wednesday, September 8 - 11:00 a.m. - 12:00 p.m. (EDT)
Register
|